Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Experimental autoimmune encephalomyelitis (EAE) serves as a model for multiple sclerosis (MS).
• Valproic acid (VPA) exhibits anti-inflammatory and neuroprotective properties.

Purpose of the Study:

• To investigate the therapeutic potential of VPA in a rat model of EAE.
• To elucidate the immunomodulatory effects of VPA in EAE.

Main Methods:

• Administration of VPA (500 mg/kg) preventively and therapeutically in EAE rats.
• Assessment of EAE clinical scores, spinal cord mRNA levels (cytokines, MMP9, iNOS, T-bet), and immune cell infiltration.
• In vitro analysis of VPA's effect on lymphocyte proliferation.

Main Results:

• VPA significantly reduced EAE severity and duration.
• VPA suppressed pro-inflammatory cytokine mRNA (IFN-γ, TNF-α, IL-1β, IL-17) and iNOS, MMP9, T-bet, while increasing IL-4 mRNA in spinal cords.
• VPA treatment decreased macrophage and lymphocyte infiltration, shifted T-helper cell profiles towards Th2 and regulatory T cells, and inhibited lymphocyte proliferation in vitro.

Conclusions:

• VPA effectively suppresses systemic and local inflammation in EAE.
• VPA demonstrates immunomodulatory effects beneficial for EAE outcome.
• VPA shows promise as a potential therapeutic agent for multiple sclerosis.